Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis B to interferon alfa.
In order to examine whether variation in interleukin-10 promoter polymorphism would predict the likelihood of sustain response of chronic hepatitis B to treatment with interferon alfa (IFN-α), the inheritance of 3 biallelic polymorphisms in the IL-10 gene promoter in patients with 52 chronic hepatitis B were determined by polymerase chain reaction (PCR)-bared techniques, restriction enzyme digestion or direct sequencing. The relationship to the outcome of antiviral therapy for chronic HBV infection was studied in 24 patients who had a virologically sustained response(SR) and in 28 non-responder(NR) to interferon alfa-2b and several IL-10 variants were more frequent among SR compared with NR. Carriage of the -592A allele, -592A/A genotype and -1082/-1819/-592 ATA haplotype was associated with SR. Our findings indicate that heterogeneity in the promoter region of the IL-10 gene has a role in determining the initial response of chronic hepatitis B to IFN-α therapy.
Department of Infectious Diseases, the Fuzhou General Hospital, Fu Zhou, Fujian Province 350003, China. wsy_fz@hotmail.com
Shaoyang
S
Wang
Dedong
D
Huang
Shunlai
S
Sun
Weimin
W
Ma
Qin
Q
Zhen
D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005787:Gene Frequency; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D016898:Interferon-alpha / Q000276:immunology / Q000627:therapeutic use*; D016753:Interleukin-10 / Q000235:genetics* / Q000276:immunology*; D008297:Male; D016133:Polymerase Chain Reaction; D011110:Polymorphism, Genetic; D012150:Polymorphism, Restriction Fragment Length; D011401:Promoter Regions, Genetic; D017422:Sequence Analysis, DNA; D016896:Treatment Outcome
D000998:Antiviral Agents; C508609:IL10 protein, human; D016898:Interferon-alpha; D016753:Interleukin-10
Hepatology. 1999 Aug;30(2):526-30
10421663
Int J Immunogenet. 2008 Jun;35(3):255-64
18479293
Lancet. 2005 Jan 8-14;365(9454):123-9
15639293
Gastroenterology. 2010 Jan;138(1):165-72.e1-3
19782084
J Immunol. 2003 Nov 1;171(9):4708-16
14568946
Liver Int. 2010 Nov;30(10):1448-53
20825556
Arch Med Res. 2008 May;39(4):420-8
18375254
N Engl J Med. 2005 Jun 30;352(26):2682-95
15987917
Adv Immunol. 1994;56:1-26
8073945
N Engl J Med. 1997 Jan 30;336(5):347-56
9011789
Pathol Biol (Paris). 2010 Aug;58(4):273-7
20378277
Annu Rev Med. 2001;52:29-49
11160766
Viral Immunol. 2010 Jun;23(3):251-7
20565290
Lancet Infect Dis. 2002 Jan;2(1):43-50
11892495
Int J Cancer. 1997 May 16;71(4):630-7
9178819
Lancet. 1997 Jun 28;349(9069):1912-3
9217780
Liver Int. 2006 Apr;26(3):326-33
16584395
Liver. 2002 Oct;22(5):404-12
12390476
Am J Gastroenterol. 2002 Aug;97(8):2086-92
12190181
J Viral Hepat. 2009 Sep;16(9):674-80
19714778
J Gen Virol. 2006 Jun;87(Pt 6):1439-1449
16690908
Genes Immun. 1999 Nov;1(2):151-5
11196662
Hepatology. 2010 Oct;52(4):1251-7
20830787
Vaccine. 2009 Nov 5;27(47):6550-7
19729084
Annu Rev Immunol. 2001;19:65-91
11244031
Hepatology. 2000 Apr;31(4):828-33
10733535
J Immunol. 1991 May 15;146(10):3444-51
1827484